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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of resistance to the fluoroquinolones
in patient specimens or culture isolates confirmed as TB positive.
To obtain summary estimates of the diagnostic accuracy of GenoType®MTBDRsl for detection of resistance to second-line injectable
drugs in patient specimens or culture isolates confirmed as TB positive.
To obtain summary estimates of the diagnostic accuracy of GenoType® MTBDRsl for detection of XDR-TB in patient specimens or
culture isolates confirmed as TB positive.
Purpose of index test: GenoType® MTBDRsl used as an initial test replacing phenotypic culture-based DST as the initial test.
We plan to investigate heterogeneity in relation to the reference tests (genetic sequencing, culture-based DST, and culture-based DST
followed by genetic sequencing), as well as by type of testing (indirect or direct). We also plan to investigate heterogeneity in relation
to HIV status, conditions of the specimens (fresh or frozen, volume of specimen) and patient population (patients suspected of having
MDR-TB or XDR-TB).
B A C K G R O U N D
Tuberculosis (TB) is an infectious airborne disease caused byMy-
cobacterium tuberculosis and is the second most common cause of
death from an infectious disease in adults (HIV/AIDS being first).
TB predominantly affects the lungs (pulmonary TB) but can af-
fect other parts of the body, such as the brain or the spine. Ac-
tive TB disease is confirmed by finding viable TB bacilli in fluid
or tissue. The symptoms of active pulmonary TB include a per-
sistent cough (for at least two weeks), fever, night sweats, weight
loss, chills, haemoptysis, and fatigue. In 2011, an estimated 8.7
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million people developed TB and 1.4 million people died from
TB. TB that is drug sensitive (also referred to as drug-susceptible
TB) may be effectively treated with a standardized regimen of first-
line anti-TB drugs, along with supervision and support (WHO
2012). However, TB bacilli may become drug resistant, meaning
that first-line anti-TB drugs no longer kill TB bacilli. Drug-resis-
tance usually develops because of inappropriate or incorrect use of
first-line drugs.
The global emergence of drug-resistant TB (DR-TB) threatens to
destabilise global TB control. In 2010, approximately 5% of the
8.8 million new cases of TB were drug resistant (WHO 2009;
WHO 2012). Therapy for DR-TB requires treatment for more
than 12 months, is toxic, and exceptionally expensive. In South
Africa, treatment of approximately 6000 cases of DR-TB con-
sumes approximately 60% of the country’s annual TB drug bud-
get). Fifty percent to 75%of patients experience unfavourable out-
comes, such as death, treatment failure, or adverse drug reactions
(Dheda 2010a; Dheda 2010b). There are two standardized defini-
tions of DR-TB: multidrug-resistant TB (MDR-TB) and exten-
sively drug resistant TB (XDR-TB). MDR-TB is caused byM. tu-
berculosis which, when tested microbiologically in the laboratory,
is resistant to rifampicin and isoniazid. These drugs are two of the
most effective and widely-used anti-TB drugs that form part of the
standardized first-line regimen for drug-susceptible TB. Patients
withMDR-TB are commonly treated with fluoroquinolone drugs
and second-line injectable drugs. Fluoroquinolone drugs include
ofloxacin and moxifloxacin. Second-line injectable drugs include
amikacin and kanamycin (two aminoglycoside drugs) and capre-
omycin (a cyclic peptide drug). XDR-TB is caused by M. tuber-
culosis resistant to isoniazid, rifampicin, plus any fluoroquinolone
and at least one of the three injectable second-line drugs (amikacin,
kanamycin, or capreomycin). Hence, patients with XDR-TB are
resistant to both first-line and second-line drugs.
In South Africa, 80% of MDR-TB is thought to be spread via
person-to-person transmission (Streicher 2011), and the same is
likely true of XDR-TB in China (Zhao 2012). Modelling studies
(Basu 2007; Dowdy 2008; Basu 2009) have shown that, through
the expansion of capacity to rapidly diagnose DR-TB, patient cure
rates will be improved through the earlier initiation of appropriate
and effective TB treatment. Importantly, once a patient is placed
on effective treatment their infectiousness dramatically declines
(within one to two weeks) (Menzies 1997). Early treatment ini-
tiation may therefore help curtail the spread of DR-TB through
the disruption of person-to-person transmission. There is thus an
urgent need for rapid tests that allow for the early detection of
drug resistance and the selection of appropriate TB drugs.
Conventional tests for detecting TB drug resistance, referred to as
drug susceptibility testing (DST), are traditionally ’phenotypic’,
in that biological fluid from the patient (usually sputum) is in-
oculated into a culture medium containing the drug of interest
and the presence (indicating resistance) or absence (indicating sus-
ceptibility) of M. tuberculosis growth is detected (Heysell 2012).
Such testing is commonly performed indirectly, in that the pure
bacterial culture or isolate grown from the original patient speci-
men is re-inoculated into drug-containing media. As the growth
of M. tuberculosis typically takes between two to six weeks for the
initial culture, there is often a significant time delay (two to six
months) associated with the diagnosis of DR-TB, especially if re-
inoculation is required. These delays are often further exacerbated
by the technical and infrastructure requirements of tests, a lack of
standardised methodologies for certain drugs (which cause unclear
results that require repeating) (Richter 2009), as well as patient-as-
sociated difficulties, such as loss to follow-up. Recently, new com-
mercial tests for drug resistance, which are frequently ’genotypic’
in nature and detect the presence of specific mutations known
to be associated with drug resistance, have offered considerable
promise for the diagnosis of DR-TB.
One of the challenges in this review is the choice of the refer-
ence standard used to determine the presence or absence of the
target conditions (described below). The best reference standard
for testing for the presence of drug resistance is generally consid-
ered to be genetic sequencing. However, because of the technical
aspects, costs, and time associated with this method, it is rarely
feasible to perform sequencing on all samples suspected of DR-
TB. The most widely used reference standard for drug resistance
testing, phenotypic culture-based DST, is considered substantially
imperfect, being likely to assign a false-positive result in situations
where the index test result is positive and the reference standard
result is negative. Recognizing that phenotypic DST is imperfect,
researchers may perform genetic sequencing for selected samples
where index test and phenotypic DST reference standard results
do not agree (usually index test positive/phenotypic DST refer-
ence standard negative). In this scenario, selected TB samples (not
all) with discordant results will receive a second reference standard
test (namely genetic sequencing) to resolve the discordant results.
This type of analysis is referred to as discrepant analysis. In the
review, we plan to look at the different reference standards as a
potential methodological source of heterogeneity.
Target condition being diagnosed
We will consider the following three target conditions: resistance
ofM. tuberculosis to fluoroquinolones; resistance ofM. tuberculosis
to second-line injectable drugs; and XDR-TB.
Index test(s)
The GenoType® MTBDRsl assay (Hain Life Sciences) detects
mutations in the gyrA gene (encoding the A-subunit of DNA gy-
rase), the rrs gene (encoding the 16S rRNA complex) and the
embB gene (which, together with the genes embA and embC, codes
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for arabinosyltransferase) of the TB-causing M. tuberculosis com-
plex species (which includes M. tuberculosis,M. africanum,M. bo-
vis subsp. bovis,M. bovis subsp. caprae,M. bovis subsp. BCG,M.
microti,M. canetti, andM. pinnipedii) (Hain Life Sciences 2012a).
The presence of mutations in these genes is associated with re-
sistance to the fluoroquinolones (including ofloxacin and lev-
ofloxacin), second-line injectable drugs (including kanamycin,
amikacin, and capreomycin), and ethambutol, respectively. Since
ethambutol is a first-line drug, we will not determine the accuracy
of GenoType® MTBDRsl assay for ethambutol resistance in the
review.
The assay can be performed either on a patient specimen (direct
testing) or on a culture grown from the patient specimen (indirect
testing). This is dependent on the quantity of TB in the patient
specimen. The manufacturer recommends that if the specimen
contains bacilli that can be seen using a light microscope and an
acid-fast stain (smear-positive), the assay is performed directly on
the specimen (Figure 1). The assay procedure is comprised of three
sequential steps when using direct decontaminated patient ma-
terial [decontaminated using the standard N-acetyl-cysteine and
sodium hydroxide (NALC/NaOH method)], culture isolates in
liquid media, or when picking colonies from solid media. These
steps are: (1) Mycobacterial genomic DNA is extracted from the
patient specimen or culture isolate; (2) regions within the gyrA, rrs
and embB genes are selectively amplified using a multiplex poly-
merase chain reaction (PCR) assay; and (3) the amplification prod-
ucts are lastly detected on a nitrocellulose membrane strip by re-
verse hybridisation and visualised using a streptavidin-conjugated
alkaline phosphatase colour reaction. The observed bands, each
corresponding to a specific probe, can be used to determine the
drug susceptibility profile of the analysed specimen (an example is
shown in Figure 2). The extraction can also be done indirectly on
blood cultures, where a 6.6 Middlebrook slant is inoculated prior
to picking the colonies from the agar after incubation for a period
of time.
Figure 1. Clinical pathway diagram showing how molecular drug susceptibility testing (DST), such as
testing with the MTBDRsl assay, is applied. A patient with suspected TB or suspected drug-resistant TB
supplies a biological specimen (usually sputum), which is examined by smear microscopy and cultured. If acid-
fast bacilli are observed under the microscope (smear-positive), the molecular DST can be performed directly
on the specimen. If acid-fast bacilli are not observed (smear-negative), molecular DST can only be performed
with acceptable accuracy on the culture isolate grown from the specimen. A molecular test for first-line drug
resistance (e.g. the MTBDRplus assay) is performed first and, only if resistance to the first-line drugs is
indicated, is tested further for resistance to the second-line drugs performed using the MTBDRsl assay. Where
molecular testing is not available, phenotypic testing for drug resistance is typically performed on culture-
positive isolates. This phenotypic testing is being replaced by molecular-based methods as indicated. However,
as represented by the dashed lines, it is still usually performed in research studies seeking to measure the
accuracy of the molecular test. Furthermore, some research studies also perform gene sequencing on any
specimens with discordant results.
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Figure 2. Examples of different GenoType® MTBDRsl strip readouts.
A template is supplied by the manufacturer to help read the strips
(Figure 3) where the banding patterns are scored by eye, tran-
scribed, and manually fed into the Laboratory Information Sys-
tem (LIS). In high-volume settings, an automated reader, the
GenoScan®, can be incorporated to interpret the banding pat-
terns automatically and give a suggested interpretation (an exam-
ple output of the machine is shown in Figure 4). If the operator
agrees with the interpretation, the results are automatically down-
loaded into the LIS, thus eliminating possible transcription errors.
It is important to note that the automated reader only provides
a suggested result, and requires manual confirmation of the re-
sult after the operator has visually inspected the banding pattern.
Nonetheless, the test manual provides fairly straightforward in-
struction with little room for variation in interpretation, even hu-
man interpretation. The entire assay procedure can be completed
in five hours. The assay can also be performed on DNA from pure
isolates taken from cultured patient specimens. Once a diagnosis
ofMDR-TBhas been established, theGenoType®MTBDRsl can
also be used to confirm a diagnosis of XDR-TB.
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Figure 3. An example of the manufacturer-supplied result template.
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Figure 4. Example of a readout from an automated strip reader. The results are generated automatically
and validated manually by a technician.
An example of different GenoType® MTBDRsl results is shown
in Figure 2. The assay consists of two internal controls (a conjugate
control for confirmation of the colorimetric reaction used to vi-
sualise bands, and an amplification control, to ensure that nucleic
acid amplification reaction has occurred), plus a control for each
gene locus (gyrA, rrs, embB). The two internal controls, plus the
locus control for the gene of interest, should always be positive;
otherwise the assay cannot be evaluated for that particular drug.
Of note is that a result can be indeterminate for one gene but valid
for another (on the basis of only the gene-specific locus control
failing). A band for the detection of the M. tuberculosis complex
(the “TUB” band) is included. Should the wild-type and/or mu-
tant probes appear whilst the locus control for a specific gene is
less intense than that of the amplification control band (AC band),
and the TUB band is interpretable, the locus probes should be
considered secondary to that of the other probes for the gene in
question and can thus be considered for interpretation. An earlier
version of the MTBDRsl manual (version 1) stated that, if the
locus band was absent but other non-control bands were present
(even together with their accompanying gene locus control bands)
the assay should be considered non-evaluable (Hain Life Sciences
2012a). However, the most recent version (version 2; Hain Life
Sciences 2012b) states: “in rare cases the TUB zone may be neg-
ative while an evaluable resistance pattern is developed. If so, the
presence of a strain belonging to the MTB complex must be sus-
pected and the assay should be repeated”. Upon inspection, most
of these are nontuberculous mycobacteria and thus if the TUB
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band is not present, it is suggested to use the GenoType® CM/
AS kit for the identification of other common mycobacteria, or
additional species should the GenoType® CM/AS kit fail to pro-
duce a positive identification for any of the 17 species covered by
the GenoType® CM/AS kit. The manufacturer also recommends
that if resistance to the fluoroquinolones or any of the second-line
injectables is detected, but resistance to ethambutol is not, addi-
tional phenotypic testing should be performed in order to exclude
ethambutol resistance.
Clinical pathway
The clinical pathway is shown in (Figure 1). Depending on the
setting, DST is either performed on all patients with confirmed
TB, or only on patients who are clinically suspected of having
DR-TB (for example, if the patient has been failing therapy). The
manufacturer recommends that, if the patient specimen (usually
sputum) is smear-positive, the assay be performed directly on the
specimen (direct testing). If smear-negative, it is recommended
that the assay be performed on the culture isolate grown from the
patient specimen (indirect testing). DST for resistance to the sec-
ond-line drugs is only performed if resistance to the first-line drugs
is confirmed. Where routine molecular (genotypic) testing is well
established, phenotypic DST is not usually performed, however,
we expect research studies evaluating the accuracy of molecular
DSTs, such as the MTBDRsl test, to almost always include phe-
notypic DST as a reference standard. Furthermore, we also expect
some studies to use genetic sequencing to resolve any discordant
index test-reference standard results.
Prior test(s)
As detailed in Figure 4 patients who received MTBDRsl testing
will first have received (i) smear microscopy, (ii) liquid culture
(if smear-negative), and (iii) phenotypic or genotypic DST for
resistance to first-line drugs.
Role of index test(s)
Diagnosis of resistance to the fluoroquinolone drugs and the sec-
ond-line injectable drugs, and the diagnosis of XDR-TB
Rationale
Second-line TB drugs are used to treat patients with TB that is
resistant to the most effective and widely used first-line drugs. To
ensure that themost appropriate and least toxic drugs are provided
to patients as quickly as possible, it is critical to know whether
a patient has resistance to fluoroquinolones alone; resistance to
second-line injectable drugs alone; or resistance to both fluoro-
quinolones and second-line injectable drugs (XDR-TB) as this will
guide the selection of drugs. In addition, the presence of XDR-
TB has major prognostic implications for the patient and for in-
fection control. The conventional method for the diagnosis of
drug resistance is slow and can take several months. The resulting
diagnostic delay results in unnecessary morbidity, mortality, and
increased transmission, which is a major driver of new TB cases.
There is a need for rapid assays to improve time-to-diagnosis and
new molecular assays, such as the GenoType® MTBDRsl assay,
present a promising potential solution to this problem. To date,
we are aware of approximately 15 studies examining the diagnos-
tic accuracy of this assay for resistance to second-line drugs. Some
of these studies have been performed by direct testing on patient
specimens and other studies have been performed by indirect test-
ing on pure culture isolates grown from patient specimens.
O B J E C T I V E S
To obtain summary estimates of the diagnostic accuracy of
GenoType® MTBDRsl for detection of resistance to the fluoro-
quinolones in patient specimens or culture isolates confirmed as
TB positive.
To obtain summary estimates of the diagnostic accuracy of Geno-
Type® MTBDRsl for detection of resistance to second-line in-
jectable drugs in patient specimens or culture isolates confirmed
as TB positive.
To obtain summary estimates of the diagnostic accuracy of Geno-
Type®MTBDRsl for detection of XDR-TB in patient specimens
or culture isolates confirmed as TB positive.
Purpose of index test: GenoType® MTBDRsl used as an initial
test replacing phenotypic culture-based DST as the initial test.
Secondary objectives
We plan to investigate heterogeneity in relation to the reference
tests (genetic sequencing, culture-based DST, and culture-based
DST followed by genetic sequencing), as well as by type of testing
(indirect or direct). We also plan to investigate heterogeneity in
relation toHIV status, conditions of the specimens (fresh or frozen,
volume of specimen) and patient population (patients suspected
of having MDR-TB or XDR-TB).
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We will include all studies that determine the diagnostic accuracy
of the index test in comparison with a defined reference standard.
Such studies are typically cross-sectional in nature. However, we
will include all types of study designs, including case-control de-
signs, in which cases and controls are sampled from the same pa-
tient population if we do not have sufficient cross-sectional stud-
ies. For multi-site studies that tested the same panel of TB isolates,
we will select one site based on the experience of the laboratory
technicians (some experience, but not extensive experience with
the assay) and results that fell in the middle range (neither the
best nor the worst results and represenative of the other sites). We
will only include studies from which data can be extracted for true
positives (TP), true negatives (TN), false positives (FP), and false
negatives (FN).
Participants
We will include patients/specimens of any age who are suspected
of having resistance to any of the second-line TB drugs, as well as
patients/specimens with confirmed MDR-TB, from all settings.
Index tests
We will include studies that evaluate the GenoType® MTBDRsl
assay.
Target conditions
We will consider three target conditions:
1. Resistance to any of the fluoroquinolones. The
fluoroquinolones include ofloxacin, levofloxacin, and
moxifloxacin.
2. Resistance to any of the second-line injectable drugs. The
second-line injectable drugs include two aminoglycosides,
kanamycin and amikacin, and one cyclic peptide, capreomycin.
3. XDR-TB
For the fluoroquinolones, the presence of mutations in each of the
genes probed by the MTBDRsl assay has very high concordance
with resistance to all drugs within that drug class (for example,
a mutation in the gyrA usually means a strain is resistant to each
of the fluoroquinolones: ofloxacin, levofloxacin, and moxifloxacin
(Sirgel 2012b). The same holds true for the rrs gene and the two
aminoglycosides, kanamycin and amikacin (Sirgel 2012a). In ref-
erence to capreomycin, the evidence is mixed regarding the level of
concordance between resistance to the two aminoglycosides and
capreomycin arising from mutations in the rrs gene. We acknowl-
edge that determining resistance to all three second-line injectables
drugs together, and thus including careomycin with the amino-
glycosides, may be a limitation. However, the index test results are
reported in this manner. We will discuss concerns about detection
of capreomycin resistance in the review.
Reference standards
The following reference standards will be used to define the target
conditions:
1. Genetic sequencing of the gyrA and rrs genes
2. Phenotypic culture-based DST: solid culture or a
commercial liquid culture system (BACTEC 460, MGIT 960,
and MGIT Manual System, Becton Dickinson, USA)
incorporating the drug of interest.
3. Two reference standards used sequentially: phenotypic
culture-based DST followed by selective testing by genetic
sequencing of samples with discordant results (also referred to as
discrepant analysis). Discordant results may be either index test
positive/phenotypic culture-based DST negative or index test
negative/phenotypic culture-based DST positive.
There are strengths and limitations to each of the reference stan-
dards. Phenotypic culture-based DST is the conventional refer-
ence standard, but it is considered to be less than 100% accurate in
verifying the target conditions. Genetic sequencing is considered
to be more accurate than phenotypic culture-based DST; however,
genetic sequencing is usually applied only to culture isolates when
results for index test/phenotypic culture-based DST do not agree.
In this latter situation, there is potential for risk of bias (verifica-
tion bias) because the same reference standard is not being used
to verify all index test results. Another limitation of genetic se-
quencing is that this method may not target all of the resistance-
determining regions in the TB genome.
We will carry out separate analyses for the three different reference
standards. In our primary analysis we will use genetic sequencing
as the reference standard, though we anticipate few studies will use
this reference standard for all samples. We will investigate the po-
tential contribution of the different reference standards as sources
of heterogeneity by performing two secondary analyses using the
following reference standards: phenotypic culture-based DST (we
expect all or nearly all studies included in the review to report
results using this reference standard) and two reference standards
used sequentially, ie phenotypic culture-based DST followed by
selective use of genetic sequencing for discordant results.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, and
ongoing).
Electronic searches
To identify all relevant studies, we will search the follow-
ing databases using the search terms and strategy described in
Appendix 1: Cochrane Infectious Diseases Group SpecializedReg-
ister; MEDLINE; EMBASE; ISI Web of Knowledge; MEDION;
LILACS;BIOSIS; andSCOPUS.Wewill also search themetaReg-
ister of Controlled Trials (mRCT) and the search portal of the
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World Health Organization (WHO) International Clinical Trials
Registry Platform (www.who.int/trialsearch), to identify ongoing
trials. We will also search ProQuest Dissertations & Theses A&I
and the National ETD Portal (South African theses and disserta-
tions) to identify relevant dissertations.
Searching other resources
We will review reference lists of included articles and any relevant
review articles identified through the above methods.We will con-
tact the assay manufacturer (Hain Life Sciences) to identify un-
published studies. We will contact researchers at the Foundation
for Innovative NewDiagnostics (FIND), members of the StopTB
Partnership’s New Diagnostics Working Group, and other experts
in the field of TB diagnostics for information on ongoing or un-
published studies.
Data collection and analysis
Selection of studies
Two independent review authors (GTand JP)will first look at titles
and abstracts identified by electronic literature searching to iden-
tify potentially eligible studies.Wewill select all citations identified
as suitable by the two review authors during this screen (screen 1)
for full-text review. Two independent review authors (GT and JP)
will then review full-text papers (screen 2) for study eligibility us-
ing the predefined inclusion and exclusion criteria. During screen
2, we will resolve any discrepancies by discussion between the two
review authors (GT and JP), or if they are unable to resolve, by
the decision of a third review author (KRS). We will maintain a
list of excluded studies and their reasons for exclusion.
Data extraction and management
Two independent review authors (GT and JP) will extract a set of
data from each study using a piloted data extraction form. Based
on the pilot data extraction, the extraction form will be finalized.
Two independent review authors (GT and JP) will then extract
data on the following characteristics:
• Details of study: first author; publication year; case country
of residence; World Bank country income status; setting
(primary care laboratory, hospital laboratory, reference
laboratory); study design; manner of participant selection;
number of participants enrolled; number of participants for
whom results available; industry sponsorship.
• Characteristics of participants: age (mean, SD; median,
interquartile range; age range); HIV status; smear status; history
of TB; known MDR-TB, pre-XDR-TB, or XDR-TB status.
• Target conditions: resistance to fluoroquinolones; resistance
to second-line injectable drugs; XDR-TB.
• Reference standards: (name and manufacturer); type;
percentage of patients whose reference standard was
‘indeterminate’ (contaminated, sequencing failed etc.).
• Details of specimen: type (such as expectorated sputum,
induced sputum, or culture isolate); condition (fresh or frozen);
definition of a positive smear, type of testing (direct testing or
indirect testing).
• Details of outcomes: the number of true positives (TP), true
negatives (TN), false positives (FP), and false negatives (FN);
number of indeterminate, missing, or unavailable assay results.
• Time to treatment initiation - defined as the time from
specimen collection until patient starts treatment.
• Time to diagnosis - defined as the time from specimen
collection until there is an available TB result in lab or clinic, if
the assay was performed in a clinic.
We will contact authors of primary studies for missing data or
clarifications. We will enter all data into a database manager.
Whenever possible, we will extract data that use patient as the unit
of analysis, ie one Genotype®MTBDRsl result per one specimen
from one patient. However, some of the studies may provide data
using ’specimen’ as the unit of analysis, meaning in some situations
one patient may have submitted more than one specimen. We will
therefore, in sensitivity analyses for each target condition, compare
pooled sensitivity and specificity for detection of drug resistance
in all studies with pooled sensitivity and specificity in the subset
of studies that provides one result per patient.
Assessment of methodological quality
We will appraise the quality of included studies with the Qual-
ity Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool
(Whiting 2011). QUADAS-2 consists of four domains: patient
selection, index test, reference standard, and flow and timing. We
will assess all domains for the potential for risk of bias. In addi-
tion, we will assess the first three domains for concerns regard-
ing applicability. We will used specific questions, called signalling
questions, for each domain to form judgments about the risk of
bias. One review author (GT) will pilot the tool with two of the
included studies. We will finalize the tool based on experience we
gain from the pilot testing. Two review authors will independently
assessmethodological quality of included studies with the finalized
tool. We will not generate a summary “quality score” because of
problems associated with such scores (Juni 1999; Whiting 2005).
We have provided the domains of the QUADAS-2 tool and their
interpretation in Appendix 2.
Statistical analysis and data synthesis
Firstly, we will provide a descriptive analysis of the results of the
primary studies. We will provide results separately for each of the
three target conditions. We will base the results of the index test
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on categorical assay results defined by the visual readout of the
Genotype® MTBDRsl strip.
Possible results for the Genotype®MTBDRsl assay are (as defined
by the product manual):
1. Sensitive to either fluoroquinolones, or second-line
injectable drugs (referred to as ’aminoglycosides/cyclic peptides’),
or both (conjugation and amplification bands present; TUB
band present; gene locus band present; all wt bands for each gene
present; no mutation bands present).
2. Resistant to either fluoroquinolones or second-line
injectable drugs, or both (conjugation and amplification bands
present; TUB band present; gene locus band present; all, none, or
some wt bands for each gene present; all, none, or some mutation
bands present with similar intensity to amplification control).
3. Indeterminate (faint bands) or no result (no conjugation or
amplification bands present, no locus band present for the gene
of interest).
4. No TB (negative for MTB complex irrespective of locus
control band).
5. No result (failure of any one of the control bands, as well as
the TUB band).
We will consider results reported as ’indeterminate’, ’no TB’, or
’no result’ (3, 4, and 5 above) to be indeterminate index test results.
Assignment of results to the fluoroquinolones and/or
second-line injectable drugs category:
The GenoType® MTBDRsl assay detects the presence of muta-
tions in genes that cause drug resistance to fluoroquinolones, or
second-line injectable drugs, or both. It does not report whether
there is resistance to individual drugs within these categories
(ofloxacin and levofloxacin in the case of the fluoroquinolones;
amikacin, kanamycin, and capreomycin in the case of second-line
injectable drugs). Thus, one study might use phenotypic DST for
detection of kanamycin resistance and another study might use
phenotypicDST for detection of amikacin resistance as a reference
standard to confirm second-line injectable drug resistance. In such
a scenario, if the phenotypic DST and GenoType® MTBDRsl
assay results were concordant and positive for resistance, we would
classify this as second-line injectable drug resistance. We would
adopt the same approach for the fluoroquinolones. Similarily, if
the index tests reports resistance to a second-line injectable drug,
and, in the case of genetic sequencing being used as a reference
standard, the presence of mutations in the rrs gene is confirmed,
we would record this as a concordant result positive for second-
line injectable drugs.
We will perform descriptive analyses using Stata version 12.0 and
will display key study characteristics in tables. For each study we
will determine sensitivity and specificity of the assay along with
the 95% confidence intervals (CIs) and generate forest plots using
Review Manager (RevMan).
Where sufficient data are available, we will undertake meta-anal-
yses to estimate the pooled sensitivity and specificity. We will use
the following approach: firstly, we will group studies according to
the target condition evaluated. Since the index test uses a common
threshold for a positive result, we will use the bivariate random-
effects regression model (Reitsma 2005; Macaskill 2010). Then,
within each target condition, we will classify two groups accord-
ing to the type of testing, either direct testing or indirect test-
ing. For our primary analysis, we will use genetic sequencing as
the reference standard. In our investigations of heterogeneity, we
will explore the effect of using phenotypic culture-based DST as
a reference standard and culture-based DST followed by genetic
sequencing of discordant results. The following scheme demon-
strates in part how we will present results:
I. Target condition: Resistance to fluoroquinolones
A. Direct testing
1. Reference standard is genetic sequencing
2. Reference standard is culture-based DST
3. Reference standard is culture-based DST followed by
genetic sequencing
I. Target condition: Resistance to fluoroquinolones
B. Indirect testing
1. Reference standard is genetic sequencing
2. Reference standard is culture-based DST
3. Reference standard is culture-based DST followed by
genetic sequencing
II. Target condition: resistance to second-line injectable drugs
A. Direct testing
1. Reference standard is genetic sequencing
Sequence repeats as in I.A.
Investigations of heterogeneity
For each target condition, we will first investigate heterogene-
ity through visual examination of forest plots of sensitivity and
specificity. Then, if sufficient studies are available, we will explore
the possible influence of the reference tests (genetic sequencing,
culture-based DST, or culture-based DST followed by genetic
sequencing) by performing meta-analyses separately within sub-
groups defined by these tests. We expect several studies to report
TP, FP, FN, and TN values stratified by HIV status. Therefore,
we will fit themeta-analysis model separately within HIV-positive
and HIV-negative subgroups to examine the effect of this covari-
ate on the pooled sensitivity and specificity. For all subgroup anal-
yses, we will estimate test accuracy separately by type of testing,
either indirect or direct. In addition, if sufficient data are available,
we plan to investigate the effect of the condition of the specimen
(fresh or frozen), sample volume, and patient population (patients
suspected of having either MDR-TB or XDR-TB) on summary
estimates of sensitivity and specificity by adding each factor as a
covariate to the bivariate model. All covariates will be at study level
and dichotomous and are as follows:
• Condition of specimen: fresh; frozen.
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• Volume used for culture isolates: greater than or equal to 1
mL; less than 1 mL.
• Volume used for decontaminated sediment: greater than or
equal to 500 µL; less than 500 µL.
• Patient population: patients having MDR-TB; patients
suspected of having XDR-TB.
Sensitivity analyses
We will perform sensitivity analyses for three QUADAS-2 sig-
nalling questions to explore whether the results we found are ro-
bust with respect to the methodological quality of the studies. We
will pose the following questions:
• Was a consecutive or random sample of patients/specimens
enrolled?
• Were the reference standard results interpreted without
knowledge of the results of the index test?
• Did all patients receive the same reference standard?
Assessment of reporting bias
We will not undertake a formal assessment of publication bias
of data included in this review using methods such as fun-
nel plots or regression tests because such techniques have not
been found to be helpful for determining publication bias
within diagnostic test accuracy studies (Tatsioni 2005; Macaskill
2010).
Other analyses
We will summarize, if feasible, evidence on other outcomes, in-
cluding time-to-diagnosis and time-to-treatment initiation. We
will also summarize hands-on time for specimen processing and
work-flow (including the option of using the same extracted DNA
for both first-line and second-line probe assays), instrument ease-
of-use, and user satisfaction. We will address these outcomes in
a section of the discussion and we will present summary data in
additional tables.
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A P P E N D I C E S




4. exp Tuberculosis, Pulmonary/







12. 3 and 11
13. Limit 12 to ….2003-current
This is the preliminary search strategy for MEDLINE. It will be adapted for other electronic databases. All search strategies will be
reported in full in the published review.
Appendix 2. QUADAS-2 rules and interpretation
We use “patients” below with the understanding that studies in this review may be evaluating patient specimens.
Domain 1 Patient selection:
Risk of bias: Could the selection of patients have introduced bias?
Signaling question 1: Was a consecutive or random sample of patients enrolled? We will score ’yes’ if the study enrolled a consecutive or
random sample of eligible patients; ‘no’ if the study selected patients by convenience; and ’unclear’ if the study did not report the
manner of patient selection or was not clearly reported.
Signaling question 2: Was a case-control design avoided?We will score ’yes’ if the study enrolled only TB patients with suspected resistance
to second-line drugs, including patients with confirmed MDR-TB; ’no’ if the study enrolled TB patients with confirmed resistance to
second-line drugs; and ’unclear’ for all other scenarios or if it was not clearly reported.
Signaling question 3: Did the study avoid inappropriate exclusions?
We will score ’yes’ for all studies, as we do not anticipate inappropriate exclusions.
Applicability: Are there concerns that the included patients and setting do not match the review question?
We will judge ’low’ concern if the selected specimens match the review question, which reflects the way the test will be used in practice.
We will judge ’high’ concern if the selected specimens or isolates do not represent those for which the test will be used in practice, such
as in individuals who are not suspected of having DR-TB. We will judge ’unclear’ concern if we cannot tell.
Domain 2: Index test
Risk of bias: Could the conduct or interpretation of the index test have introduced bias?
Signaling question 1: Were the index test results interpreted without knowledge of the results of the reference standard? We will score this
question ’yes’ if the reader of the assay was blinded to results of reference tests. We will score ’no’ if the reader of the assay was not
blinded to the results of reference tests. If the specimens were from a biobank comprised of specimens with known second-line drug
resistance, and the identity of these specimens was known to the assay reader, we will also answer ’no’. We will score ‘unclear’ if it was
not stated in the paper or if the authors failed to answer this question.
Signaling question 2: If a threshold was used, was it prespecified? A threshold is prespecified in all versions of MTBDRsl. We will answer
this question ’yes’ for all studies.
Applicability: Are there concerns that the index test, its conduct, or its interpretation differ from the review question? Variations in test
technology, execution, or interpretation may affect estimates of the diagnostic accuracy of a test. However, we will judge these issues to
be of ’low’ concern for all studies in this review, as the Genotype® MTBDRsl assay is standardized.
Domain 3: Reference standard
Risk of bias: Could the reference standard, its conduct, or its interpretation have introduced bias?
Signaling question 1: Is the reference standard likely to correctly classify the target condition?
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Genetic sequencing (gene sequencing of loci known to be associated with drug resistance) is considered the best available reference
standard. We will answer ’yes’ when this reference standard is used. Phenotypic culture-based drug susceptibility testing is not 100%
accurate for detection of drug resistance, in particular with respect to detection of second-line drug resistance. We will answer ’unclear’
when this reference standard is used. Two reference standards used sequentially refers to culture-based drug susceptibility testing followed
by genetic sequencing. We will answer ’yes’ when this reference standard is used because genetic sequencing will be the arbiter of the
final results.
Signaling question 2: Were the reference standard results interpreted without knowledge of the results of the index test? We will score ’yes’ if
the reference test provided an automated result (e.g. MGIT 960 drug susceptibility testing), blinding was explicitly stated, or it was
clear that the reference test was performed at a separate laboratory, or performed by different people, or both. We will score ‘no’ if the
study stated that the reference standard result was interpreted with knowledge of the MTBDRsl assay result. We will score ’unclear’ if
it was not stated in the paper or if the authors failed to answer this question.
Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? We judge
applicability to be of ’low concern’ for all studies.
Domain 4: Flow and timing
Risk of bias: Could the patient flow have introduced bias?
Signaling question 1: Was there an appropriate interval between the index test and reference standard? We expect the reference standard
test to be undertaken at the same time as the index test (ie each performed on a paired sample for the majority of studies). However,
we expect some studies to include specimens from patients who have received a reference test on an earlier sample. The sample applies
to some culture isolates, whose drug susceptibility profile might have been confirmed prior to the index test being available. We will
answer this question ‘yes’ if the tests were paired or were separated by a few days. We will answer this question ’no’ if reference and
index tests were not done on paired samples and were separated by several months. As patients suspected of second-line drug resistance
are often on some form of anti-TB therapy, it is possible that variation in the microbial population of specimens collected at different
timepoints may occur. We will score ’unclear’ if it was not stated in the paper or if the authors failed to answer this question.
Signaling question 2: Did all patients receive the same reference standard?
We will answer ’yes’ if the same reference standard was applied to all patients or a random sample of patients, ’no’ if the reference
standard was only applied to a selective group of patients, and ’unclear’ if it was not stated in the paper or if the authors failed to answer
this question.
Signaling question 3: Were all patients included in the analysis?We will determine the answer to this question by comparing the number
of participants enrolled with the number of patients included in the two-by-two tables. We will note if the authors report the number
of indeterminate assay results.
We will score ‘yes’ if the number of participants enrolled was clearly stated and corresponded to the number presented in the analysis
or if exclusions were adequately described. We will score ’no’ if there were participants missing or excluded from the analysis and there
was no explanation given. We will score ’unclear’ if not enough information was given to assess whether participants were excluded
from the analysis.
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